Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health
(Thomson Reuters ONE) -
Enzymatica has partnered with Endeavour Consumer Health, a division of Symbion
which is a member of EBOS Group. The agreement grants Endeavour Consumer Health
exclusive rights to sell, market and distribute ColdZyme® in Australia and New
Zealand. It is Enzymatica's first agreement outside the European Union (EU) and
a breakthrough in the company's strategic initiative to further establish
ColdZyme in the international market.
The agreement covers the products ColdZyme 20ml and ColdZyme OneCold 7ml.
The regulatory requirements for medical devices in Australia differ from those
in the EU, meaning ColdZyme will be registered in a higher class of medical
devices. The registration process is expected to take 12-18 months and the
launch is planned for 2018, ready for the cold & flu season in Australia.
"The agreement with Endeavour Consumer Health is an important breakthrough in
our strategic international expansion outside Europe, and Endeavour Consumer
Health is the perfect partner for us. They are well established and have
significant experience launching new products to the market, which will favour
the introduction of ColdZyme in Australia and New Zealand", said Fredrik
Lindberg, CEO of Enzymatica.
EBOS Group's General Manager - Retail Services, Andrew Vidler, said ColdZyme
would complement Endeavour Consumer Health's existing product offering.
"We are very excited about the agreement with Enzymatica to sell ColdZyme in
Australia. ColdZyme is different to traditional cold therapies and fits well
into our business model to grow our business in the over the counter (OTC)
health products market with innovative new products."
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg(at)enzymatica.com
This information is information that Enzymatica AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was submitted
for publication, through the agency of the contact person set out above, at
16.00 CET on November 2, 2016.
About Enzymatica
Enzymatica AB is a Life sciences company that develops and sells medical devices
for fighting infectious diseases. In a short period of time, the company
developed ColdZyme®, a unique mouth spray for fighting colds, launched the
product in seven markets and established it as one of the bestselling cold
products in Swedish pharmacies measured in SEK. Our strategy is to continue
growing by strengthening our position on existing markets and expanding to more
geographic markets via established partners. The company's head office is in
Lund and it is listed on the Nasdaq First North. For more information, please go
to: www.enzymatica.se.
Enzymaticas Certified Adviser is Erik Penser Bankaktiebolag.
About Endeavour Consumer Health
Endeavour Consumer Health is a trans-Tasman business dedicated to providing its
retail partners and their customers with affordable, high-quality health and
personal care products.
The business was formed in 2014 from the amalgamation of Symbion Consumer
Products in Australia and the consumer division of EBOS Healthcare in New
Zealand and Australia.
Endeavour Consumer Health is part of Symbion, a member of EBOS Group Ltd. EBOS
Group is the largest and most diversified Australasian marketer, wholesaler and
distributor of healthcare, medical and pharmaceutical products.
For more information visit www.ebosgroup.com
Enzymatica Press Release Australia 161102 Final version:
http://hugin.info/160850/R/2053698/768657.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.11.2016 - 16:00 Uhr
Sprache: Deutsch
News-ID 504528
Anzahl Zeichen: 4387
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 177 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health"
steht unter der journalistisch-redaktionellen Verantwortung von
Enzymatica AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
